Researchers from Northwestern Medicine have developed lipid polymer-based nanoparticles that target key cancer drivers, called brain tumor initiating cells, in a mouse model of glioblastoma brain tumors.
“BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy,” first author Dr. Dou Yu said in prepared remarks.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Nanomedicine shuts down cells that drive cancer growth in glioblastoma appeared first on MassDevice.